Hook / Thesis
Colgate-Palmolive (CL) just proved the real business is still stubbornly profitable: Q3 2026 delivered a beat on both EPS and revenue, management raised Base Business earnings growth to 5-7%, and the company reiterated margin improvement driven by pricing and cost programs. At roughly $95.95 a share and a market cap near $76 billion, the stock offers a tradeable entry where improving execution meets a valuation that looks reasonable against steady free cash flow and a durable dividend.
This is a pragmatic, risk-aware buy: use an entry at $96.00, a stop at $89.00, and a target of $108.00 with a preferred holding period of mid term (45 trading days). The idea is to capture continued momentum from margin recovery, further organic growth in key regions, and the market re-rating Colgate back toward its multi-year technical trend.
What the company does and why the market should care
Colgate-Palmolive manufactures and distributes everyday consumer products across Oral, Personal & Home Care, and Pet Nutrition (Hill's). These categories are staple purchases with defensible brand moats, predictable cash flows, and recurring demand. The market cares because Colgate combines that defensive profile with a steady dividend (recent quarterly dividend per share $0.53) and improving operational levers — pricing, volume recovery, and cost-savings programs — that can translate into margin expansion even in a cautious consumer environment.
Results and the fundamental driver
Recent operational data give the thesis teeth. In Q3 2026 Colgate reported EPS of $0.97 (up 7% YoY and beating consensus of $0.92) and net sales of $5.37 billion, up 4.6% with 3.6% organic growth. Management attributed the improvement to a balanced mix of volume (+1.7%) and pricing (+2.0%), and raised 2026 Base Business earnings growth to 5-7% while expecting gross margin expansion.
From a cash perspective, free cash flow is healthy — trailing free cash flow sits at $3.789 billion — and valuation multiples (EV/EBITDA ~17.2, P/FCF ~20.06, P/S ~3.57) are consistent with a stable, dividend-paying consumer staples name rather than a high-growth tech multiple. The company also carries moderate leverage, with debt-to-equity at ~26.8% and a current ratio around 0.96, meaning financing risk is manageable while the business continues generating cash.
Technicals and positioning
Technically, CL is above its short- and medium-term moving averages: 10-day SMA $94.33, 20-day SMA $92.71, and 50-day SMA $89.74. Momentum indicators are constructive (RSI ~59.9, MACD bullish). Short interest is modest relative to float, with recent settle numbers indicating days-to-cover in the ~3.5-4 range. That profile supports a constructive momentum trade without extreme squeeze risk.
Valuation framing
| Metric | Value |
|---|---|
| Market Cap | $76,006,371,415 |
| Price | $95.95 |
| P/E (ttm) | ~37-38x |
| EV/EBITDA | ~17.2x |
| P/FCF | ~20.06x |
| Free Cash Flow | $3.789B |
| Dividend Yield | ~2.16% |
Plainly: CL is not a deep value flop nor an overpriced growth darling. Its multiples are what you would expect for a durable consumer stalwart that still delivers steady cash flow and a multi-decade dividend track record. The case for a valuation re-rate to the upside rests on continued margin expansion and the market rewarding stability plus modest growth as macro uncertainty fades into year-end.
Catalysts (2-5)
- Continued margin recovery: management expects gross margin expansion; further evidence of expansion in upcoming releases could materially move the multiple.
- Organic sales acceleration in Latin America and Asia Pacific: regions that showed strength in Q3 and could sustain higher top-line growth rates.
- Positive surprises in Hill's Pet Nutrition: premiumization and share gains there can boost both revenue growth and margins.
- Interest from dividend/income funds as yields remain attractive relative to low-risk alternatives — a steady dividend plus a 63-year increase streak remains compelling to income buyers.
Trade plan (actionable)
Entry Price: $96.00
Stop Loss: $89.00
Target Price: $108.00
Trade Direction: Long
Time Horizon: mid term (45 trading days)
Why this setup? The entry sits close to current market levels to capture near-term momentum while giving the trade room to breathe. The stop at $89.00 respects the 50-day SMA area ($89.74) and limits downside if momentum fails. The $108 target is achievable given modest multiple expansion (EV/EBITDA and P/FCF compression reversal) plus incremental earnings upside from the 5-7% Base Business earnings growth that management now expects.
Position sizing guidance: treat this as a medium-risk swing trade sized appropriately within a diversified portfolio. Monitor upcoming sales/margin commentary and regional sales trends; be prepared to tighten stops if short-term momentum weakens near the entry.
Counterargument
A reasonable counterargument is that Colgate is a mature, low-growth consumer company that already commands a relatively full multiple given its limited upside runway. P/E in the high 30s and P/FCF ~20 leave less room for valuation multiple expansion unless growth or margin improvement is sustained. If pricing power fades or inflation re-accelerates raw-material costs, margin expansion could stall and the stock could trade sideways or re-test the low $75 range we saw over the past year.
Risks (at least 4)
- Macro-driven soft consumer spending - heightened price sensitivity could force deeper promotional activity, squeezing margins and volume.
- Commodity and logistics inflation - renewed inflation pressure could erode gross margins before pricing and cost programs catch up.
- Execution risk on margin programs - if cost-savings or productivity initiatives underperform, operating leverage will be muted.
- Regional volatility - North American declines or weakness in key emerging markets could offset gains elsewhere and reduce consolidated growth.
- Valuation sensitivity - the current P/E and P/FCF leave little room for disappointment; earnings misses could trigger outsized price declines.
What would change my mind
I would downgrade the trade if we saw any of the following: a) a meaningful miss in the next quarterly release, particularly on organic sales or margins; b) guidance reset lower on Base Business earnings growth; c) signs that pricing elasticity is materially worse than management expects; or d) a breakdown in technical support under the $89 area on sustained volume. Conversely, I would add to the position if Colgate reports another quarter of margin expansion and the stock breaks sustainably above $100 on above-average volume, signaling that both earnings and sentiment are improving.
Bottom line
Colgate-Palmolive is not a high-flying growth story, but the company is executing: Q3 beats, improved organic growth, margin tailwinds, and strong free cash flow create a favorable risk-reward for a mid-term long trade. With an entry at $96.00, stop at $89.00, and target of $108.00 over ~45 trading days, this setup aims to capture a re-rating backed by real operational momentum rather than pure multiple expansion. Position size prudently and monitor upcoming regional and margin data closely.
Key data points referenced: Q3 EPS $0.97, net sales $5.37B, organic sales +3.6%, volume +1.7%, pricing +2.0%, management Base Business earnings growth guidance 5-7%, market cap ~ $76B, free cash flow $3.789B, EV/EBITDA ~17.2, P/FCF ~20.06, current price ~$95.95.